Gallbladder Cancer – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Gallbladder Cancer – Pipeline Review, H2 2017’, provides an overview of the Gallbladder Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gallbladder Cancer

The report reviews pipeline therapeutics for Gallbladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gallbladder Cancer therapeutics and enlists all their major and minor projects

The report assesses Gallbladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gallbladder Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gallbladder Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gallbladder Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Advenchen Laboratories LLC

Array BioPharma Inc

Aslan Pharmaceuticals Pte Ltd

Bayer AG

BeiGene Ltd

Eli Lilly and Co

Halozyme Therapeutics Inc

Hutchison MediPharma Ltd

Ipsen SA

Kringle Pharma Inc

Leap Therapeutics Inc

MedImmune LLC

Molecular Templates Inc

Novartis AG

NuCana Plc

OncoTherapy Science Inc

VasGene Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Gallbladder Cancer - Overview 7

Gallbladder Cancer - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Gallbladder Cancer - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 18

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Gallbladder Cancer - Companies Involved in Therapeutics Development 25

4SC AG 25

Advenchen Laboratories LLC 25

Array BioPharma Inc 25

Aslan Pharmaceuticals Pte Ltd 26

Bayer AG 26

BeiGene Ltd 27

Eli Lilly and Co 27

Halozyme Therapeutics Inc 28

Hutchison MediPharma Ltd 28

Ipsen SA 29

Kringle Pharma Inc 29

Leap Therapeutics Inc 30

MedImmune LLC 30

Molecular Templates Inc 30

Novartis AG 31

NuCana Plc 31

OncoTherapy Science Inc 32

VasGene Therapeutics Inc 32

Gallbladder Cancer - Drug Profiles 33

apatinib mesylate - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

BGBA-317 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

binimetinib - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

copanlisib hydrochloride - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

DKN-01 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

durvalumab - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

evofosfamide - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

HMPL-012 - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

irinotecan hydrochloride - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

merestinib - Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

NK-4 - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

NUC-1031 - Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

OCVC-01 - Drug Profile 123

Product Description 123

Mechanism Of Action 123

R&D Progress 123

pazopanib hydrochloride - Drug Profile 124

Product Description 124

Mechanism Of Action 124

R&D Progress 124

PEGPH-20 - Drug Profile 133

Product Description 133

Mechanism Of Action 133

R&D Progress 133

ramucirumab - Drug Profile 143

Product Description 143

Mechanism Of Action 143

R&D Progress 143

resminostat - Drug Profile 155

Product Description 155

Mechanism Of Action 155

R&D Progress 155

trametinib dimethyl sulfoxide - Drug Profile 165

Product Description 165

Mechanism Of Action 165

R&D Progress 165

varlitinib - Drug Profile 170

Product Description 170

Mechanism Of Action 170

R&D Progress 170

Vas-01 - Drug Profile 175

Product Description 175

Mechanism Of Action 175

R&D Progress 175

Gallbladder Cancer - Dormant Projects 177

Appendix 178

Methodology 178

Coverage 178

Secondary Research 178

Primary Research 178

Expert Panel Validation 178

Contact Us 178

Disclaimer 179

List of Tables

List of Tables

Number of Products under Development for Gallbladder Cancer, H2 2017 8

Number of Products under Development by Companies, H2 2017 10

Number of Products under Development by Universities/Institutes, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Products under Development by Universities/Institutes, H2 2017 14

Number of Products by Stage and Target, H2 2017 16

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 17

Number of Products by Stage and Mechanism of Action, H2 2017 19

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 22

Number of Products by Stage and Molecule Type, H2 2017 24

Gallbladder Cancer – Pipeline by 4SC AG, H2 2017 25

Gallbladder Cancer – Pipeline by Advenchen Laboratories LLC, H2 2017 25

Gallbladder Cancer – Pipeline by Array BioPharma Inc, H2 2017 26

Gallbladder Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 26

Gallbladder Cancer – Pipeline by Bayer AG, H2 2017 27

Gallbladder Cancer – Pipeline by BeiGene Ltd, H2 2017 27

Gallbladder Cancer – Pipeline by Eli Lilly and Co, H2 2017 28

Gallbladder Cancer – Pipeline by Halozyme Therapeutics Inc, H2 2017 28

Gallbladder Cancer – Pipeline by Hutchison MediPharma Ltd, H2 2017 29

Gallbladder Cancer – Pipeline by Ipsen SA, H2 2017 29

Gallbladder Cancer – Pipeline by Kringle Pharma Inc, H2 2017 29

Gallbladder Cancer – Pipeline by Leap Therapeutics Inc, H2 2017 30

Gallbladder Cancer – Pipeline by MedImmune LLC, H2 2017 30

Gallbladder Cancer – Pipeline by Molecular Templates Inc, H2 2017 31

Gallbladder Cancer – Pipeline by Novartis AG, H2 2017 31

Gallbladder Cancer – Pipeline by NuCana Plc, H2 2017 31

Gallbladder Cancer – Pipeline by OncoTherapy Science Inc, H2 2017 32

Gallbladder Cancer – Pipeline by VasGene Therapeutics Inc, H2 2017 32

Gallbladder Cancer – Dormant Projects, H2 2017 177

List of Figures

List of Figures

Number of Products under Development for Gallbladder Cancer, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products by Top 10 Targets, H2 2017 15

Number of Products by Stage and Top 10 Targets, H2 2017 15

Number of Products by Top 10 Mechanism of Actions, H2 2017 18

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 21

Number of Products by Stage and Routes of Administration, H2 2017 21

Number of Products by Molecule Types, H2 2017 23

Number of Products by Stage and Molecule Types, H2 2017 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports